RxDoctor Payments DataLook up a doctor →

Thresa Simon, MD

Child & Adolescent Psychiatry · Petersburg, VANPI 1003871989

Payments from drug & device makers

$1,750,302in general payments, 2019–2025

Across 1,469 payments — averaging $1191.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$1.5M
  • Neurocrine Biosciences, Inc.$75K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$66K
  • Shire North American Group Inc$55K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$41K
  • Pfizer$34K
  • plus $25K from 18 others

What the payments were for

  • Food & beverage$2,18098%
  • Education$492%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,750,302 in reported general payments places this provider in the 95th percentile of 115 child & adolescent psychiatry providers in Virginia.

See all child & adolescent psychiatry providers in Virginia

Medicare billing

Part B allowed, 2024
$52,186
Medicare patients
148
Services billed
643

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate13$36,951
Aripiprazole34$3,014
Ziprasidone Hcl23$975
Naltrexone Hcl14$833
Duloxetine Hcl19$627
Trazodone Hcl55$511
Temazepam16$494
Topiramate46$467
Lithium Carbonate30$406
Risperidone40$383
Escitalopram Oxalate31$377
Quetiapine Fumarate26$332
Benztropine Mesylate17$246
Olanzapine15$237
Propranolol Hcl21$223

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$256$36,95113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 115 child & adolescent psychiatry providers in Virginia.

Other child & adolescent psychiatry in Petersburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →